Skip to main
RNAC
RNAC logo

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics Inc demonstrates a promising outlook based on updated Phase II results, which indicate a durable clinical benefit observed at a follow-up period of one year. The company's proprietary ImmTOR immune tolerance platform and its innovative mRNA technology suggest strong potential for advancing treatments, specifically with the anticipated results from the Descartes-08 study targeting systemic lupus erythematosus (SLE). Additionally, the relatively high benchmarks set by prior Auto-CAR-T therapies in the SLE space may position Cartesian to capitalize on advancements in this therapeutic area, enhancing its competitive edge and long-term value.

Bears say

Cartesian Therapeutics Inc. is facing a negative outlook due to recent adjustments in financial projections, highlighted by a lowered price target that does not correlate with expectations for growth or revenue generation. The company's reliance on its ImmTOR platform and mRNA technology may not be sufficient to offset concerns regarding operational costs and clinical development timelines. Additionally, the repeated emphasis on maintaining a buy rating despite downward price target adjustments suggests that investor confidence may be waning, potentially signaling underlying issues within the company's financial health and market position.

RNAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, RNAC has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.